Search research articles
Contact Us
Filters
Showing results (191-200 of 267) with videos related to
Page
of 27
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
June 15, 2026
Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field
Matthew J Slarve, Christine Tkaczyk, Michael P Doyle, et al.
Antimicrobial Agents and Chemotherapy
|
September 6, 2024
Polymyxins retain <i>in vitro</i> activity and <i>in vivo</i> efficacy against "resistant" <i>Acinetobacter baumannii</i> strains when tested in physiological conditions
Jennifer Rubio, Jun Yan, Sarah Miller, et al.
Medical Mycology
|
March 23, 2012
Risk factors for mortality in patients with mucormycosis
Brad Spellberg, Dimitrios P Kontoyiannis, David Fredricks, et al.
Human Vaccines & Immunotherapeutics
|
April 20, 2017
Evaluation of serotypes 5 and 8 capsular polysaccharides in protection against Staphylococcus aureus in murine models of infection
Brian L Cheng, Travis B Nielsen, Paul Pantapalangkoor, et al.
The New England Journal of Medicine
|
April 9, 2005
Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles
Loren G Miller, Francoise Perdreau-Remington, Gunter Rieg, et al.
The Journal of Clinical Investigation
|
May 21, 2010
The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice
Mingfu Liu, Brad Spellberg, Quynh T Phan, et al.
The American Journal of Medicine
|
November 28, 2017
No More 'Code Black': Intervention to Improve Inpatient Flow at a Large Public Hospital
Charles E Coffey, Valda Carter, Eric Wei, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 28, 2008
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America
Helen W Boucher, George H Talbot, John S Bradley, et al.
The Journal of Antimicrobial Chemotherapy
|
September 23, 2011
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial
Brad Spellberg, Ashraf S Ibrahim, Peter V Chin-Hong, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 17, 2012
Future directions in mucormycosis research
Dimitrios P Kontoyiannis, Russell E Lewis, Oliver Lortholary, et al.
Page
of 27
Search research articles
Search
Showing results (191-200 of 267) with videos related to
Sort By:
Page
of 27
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
June 15, 2026
Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field
Matthew J Slarve, Christine Tkaczyk, Michael P Doyle, et al.
Antimicrobial Agents and Chemotherapy
|
September 6, 2024
Polymyxins retain <i>in vitro</i> activity and <i>in vivo</i> efficacy against "resistant" <i>Acinetobacter baumannii</i> strains when tested in physiological conditions
Jennifer Rubio, Jun Yan, Sarah Miller, et al.
Medical Mycology
|
March 23, 2012
Risk factors for mortality in patients with mucormycosis
Brad Spellberg, Dimitrios P Kontoyiannis, David Fredricks, et al.
Human Vaccines & Immunotherapeutics
|
April 20, 2017
Evaluation of serotypes 5 and 8 capsular polysaccharides in protection against Staphylococcus aureus in murine models of infection
Brian L Cheng, Travis B Nielsen, Paul Pantapalangkoor, et al.
The New England Journal of Medicine
|
April 9, 2005
Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles
Loren G Miller, Francoise Perdreau-Remington, Gunter Rieg, et al.
The Journal of Clinical Investigation
|
May 21, 2010
The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice
Mingfu Liu, Brad Spellberg, Quynh T Phan, et al.
The American Journal of Medicine
|
November 28, 2017
No More 'Code Black': Intervention to Improve Inpatient Flow at a Large Public Hospital
Charles E Coffey, Valda Carter, Eric Wei, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 28, 2008
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America
Helen W Boucher, George H Talbot, John S Bradley, et al.
The Journal of Antimicrobial Chemotherapy
|
September 23, 2011
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial
Brad Spellberg, Ashraf S Ibrahim, Peter V Chin-Hong, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 17, 2012
Future directions in mucormycosis research
Dimitrios P Kontoyiannis, Russell E Lewis, Oliver Lortholary, et al.
Page
of 27